Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
The Lancet Oncology (2013) Vol. 14, Iss. 8, pp. 733-740
Closed Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reinhard Dummer, Axel Hauschild, Merlin Guggenheim, et al.
Annals of Oncology (2012) Vol. 23, pp. vii86-vii91
Open Access | Times Cited: 685
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Eva Dombi, Andrea Baldwin, Leigh Marcus, et al.
New England Journal of Medicine (2016) Vol. 375, Iss. 26, pp. 2550-2560
Open Access | Times Cited: 579
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt, Matthew J. Sale, Paul D. Smith, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 10, pp. 577-592
Closed Access | Times Cited: 554
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
Richard D. Carvajal, Jeffrey A. Sosman, J. Fernando Quevedo, et al.
JAMA (2014) Vol. 311, Iss. 23, pp. 2397-2397
Open Access | Times Cited: 397
The clinical development of MEK inhibitors
Yujie Zhao, Alex A. Adjei
Nature Reviews Clinical Oncology (2014) Vol. 11, Iss. 7, pp. 385-400
Closed Access | Times Cited: 377
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reinhard Dummer, Axel Hauschild, Nicole Lindenblatt, et al.
Annals of Oncology (2015) Vol. 26, pp. v126-v132
Open Access | Times Cited: 376
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas, et al.
Neuro-Oncology (2017) Vol. 19, Iss. 8, pp. 1135-1144
Open Access | Times Cited: 277
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Murugan Kalimutho, Kate Parsons, Deepak Mittal, et al.
Trends in Pharmacological Sciences (2015) Vol. 36, Iss. 12, pp. 822-846
Closed Access | Times Cited: 274
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 12, pp. 1232-1239
Open Access | Times Cited: 242
Systemic treatments for metastatic cutaneous melanoma
Sandro Pasquali, Andreas V. Hadjinicolaou, Vanna Chiarion‐Sileni, et al.
Cochrane library (2018) Vol. 2020, Iss. 11
Open Access | Times Cited: 220
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael A. Davies, Patrick Hwu, et al.
Oncotarget (2014) Vol. 5, Iss. 7, pp. 1701-1752
Open Access | Times Cited: 205
The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways
Andrzej Słomiński, T.-K. Kim, Anna A. Brożyna, et al.
Archives of Biochemistry and Biophysics (2014) Vol. 563, pp. 79-93
Open Access | Times Cited: 193
Targeted therapy in cancer
Apostolia M. Tsimberidou
Cancer Chemotherapy and Pharmacology (2015) Vol. 76, Iss. 6, pp. 1113-1132
Open Access | Times Cited: 187
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition
Tian Li, Shi Hu
Elsevier eBooks (2023), pp. 137-144
Closed Access | Times Cited: 69
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies, Georgina V. Long
Clinical Cancer Research (2014) Vol. 20, Iss. 8, pp. 2035-2043
Open Access | Times Cited: 147
<em>NRAS</em>-mutant melanoma: current challenges and future prospect
Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, et al.
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 3941-3947
Open Access | Times Cited: 141
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski
BioMed Research International (2015) Vol. 2015, pp. 1-16
Open Access | Times Cited: 128
Treatment of NRAS-Mutant Melanoma
Douglas B. Johnson, Igor Puzanov
Current Treatment Options in Oncology (2015) Vol. 16, Iss. 4
Open Access | Times Cited: 127
Melanoma Resistance: A Bright Future for Academicians and a Challenge for Patient Advocates
Andrzej Słomiński, J. Andrew Carlson
Mayo Clinic Proceedings (2014) Vol. 89, Iss. 4, pp. 429-433
Open Access | Times Cited: 123
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Translational Oncology (2019) Vol. 12, Iss. 6, pp. 828-835
Open Access | Times Cited: 115
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Nitin Jain, Emily Curran, Neil M. Iyengar, et al.
Clinical Cancer Research (2013) Vol. 20, Iss. 2, pp. 490-498
Open Access | Times Cited: 107
Overcoming resistance to BRAF inhibitors
Imanol Arozarena, Claudia Wellbrock
Annals of Translational Medicine (2017) Vol. 5, Iss. 19, pp. 387-387
Open Access | Times Cited: 106
Beyond BRAF: where next for melanoma therapy?
Inna V. Fedorenko, Geoffrey T. Gibney, Vernon K. Sondak, et al.
British Journal of Cancer (2014) Vol. 112, Iss. 2, pp. 217-226
Open Access | Times Cited: 103
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60
William C. Reinhold, Margot Sunshine, Sudhir Varma, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 17, pp. 3841-3852
Open Access | Times Cited: 96
OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
Silvia Méndez-Martínez, Pilar Calvo, Óscar Ruiz‐Moreno, et al.
Retina (2019) Vol. 39, Iss. 8, pp. 1435-1450
Closed Access | Times Cited: 96
Page 1 - Next Page

Scroll to top